Ronald Craig Janish Sells 7,800 Shares of Perrigo Company plc (NYSE:PRGO) Stock

Perrigo Company plc (NYSE:PRGO) EVP Ronald Craig Janish sold 7,800 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $27.44, for a total transaction of $214,032.00. Following the transaction, the executive vice president now directly owns 33,666 shares of the company’s stock, valued at $923,795.04. This represents a 18.81 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Perrigo Price Performance

Shares of PRGO opened at $27.91 on Wednesday. The company has a quick ratio of 1.77, a current ratio of 2.56 and a debt-to-equity ratio of 0.94. Perrigo Company plc has a twelve month low of $23.14 and a twelve month high of $33.46. The company has a market capitalization of $3.81 billion, a P/E ratio of -23.86 and a beta of 0.48. The firm has a 50 day moving average of $25.34 and a 200 day moving average of $26.21.

Perrigo (NYSE:PRGO) last posted its earnings results on Thursday, February 27th. The company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.01. Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.20 billion. As a group, equities research analysts anticipate that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 25th. Shareholders of record on Friday, March 7th will be given a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a yield of 4.16%. The ex-dividend date is Friday, March 7th. This is an increase from Perrigo’s previous quarterly dividend of $0.28. Perrigo’s payout ratio is -92.80%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on PRGO shares. StockNews.com downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Piper Sandler downgraded shares of Perrigo from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $34.00 to $27.00 in a research report on Monday, January 6th. Finally, Argus downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Tuesday, January 14th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, Perrigo has a consensus rating of “Hold” and an average price target of $33.00.

Institutional Investors Weigh In On Perrigo

A number of large investors have recently added to or reduced their stakes in PRGO. Headlands Technologies LLC boosted its stake in shares of Perrigo by 1,942.0% during the 4th quarter. Headlands Technologies LLC now owns 1,409 shares of the company’s stock worth $36,000 after acquiring an additional 1,340 shares during the last quarter. Versant Capital Management Inc purchased a new position in shares of Perrigo during the 4th quarter worth $45,000. GAMMA Investing LLC boosted its stake in shares of Perrigo by 93.7% during the 4th quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $49,000 after acquiring an additional 929 shares during the last quarter. Central Pacific Bank Trust Division boosted its stake in shares of Perrigo by 33.3% during the 4th quarter. Central Pacific Bank Trust Division now owns 2,000 shares of the company’s stock worth $51,000 after acquiring an additional 500 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new position in shares of Perrigo during the 3rd quarter worth $56,000. Institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.